Understanding the characteristics of nonspecific binding of drug-like compounds to canonical stem–loop RNAs and their implications for functional cellular assays
Open Access
- 7 October 2020
- journal article
- research article
- Published by Cold Spring Harbor Laboratory in RNA
- Vol. 27 (1) , 12-26
Abstract
Identifying small molecules that selectively bind an RNA target while discriminating against all other cellular RNAs is an important challenge in RNA-targeted drug discovery. Much effort has been directed toward identifying drug-like small molecules that minimize electrostatic and stacking interactions that lead to nonspecific binding of aminoglycosides and intercalators to many stem–loop RNAs. Many such compounds have been reported to bind RNAs and inhibit their cellular activities. However, target engagement and cellular selectivity assays are not routinely performed, and it is often unclear whether functional activity directly results from specific binding to the target RNA. Here, we examined the propensities of three drug-like compounds, previously shown to bind and inhibit the cellular activities of distinct stem–loop RNAs, to bind and inhibit the cellular activities of two unrelated HIV-1 stem–loop RNAs: the transactivation response element (TAR) and the rev response element stem IIB (RREIIB). All compounds bound TAR and RREIIB in vitro, and two inhibited TAR-dependent transactivation and RRE-dependent viral export in cell-based assays while also exhibiting off-target interactions consistent with nonspecific activity. A survey of X-ray and NMR structures of RNA-small molecule complexes revealed that aminoglycosides and drug-like molecules form hydrogen bonds with functional groups commonly accessible in canonical stem–loop RNA motifs, in contrast to ligands that specifically bind riboswitches. Our results demonstrate that drug-like molecules can nonspecifically bind stem–loop RNAs most likely through hydrogen bonding and electrostatic interactions and reinforce the importance of assaying for off-target interactions and RNA selectivity in vitro and in cells when assessing novel RNA-binders.Keywords
All Related Versions
Funding Information
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (U54 AI150470, F30 AI143282-01A1)
This publication has 118 references indexed in Scilit:
- Structure of a hepatitis C virus RNA domain in complex with a translation inhibitor reveals a binding mode reminiscent of riboswitchesProceedings of the National Academy of Sciences, 2012
- Quantifying the chemical beauty of drugsNature Chemistry, 2012
- New developments in aminoglycoside therapy and ototoxicityHearing Research, 2011
- Discovery of selective bioactive small molecules by targeting an RNA dynamic ensembleNature Chemical Biology, 2011
- Illuminating Insights into Firefly Luciferase and Other Bioluminescent Reporters Used in Chemical BiologyChemistry & Biology, 2010
- Pentamidine reverses the splicing defects associated with myotonic dystrophyProceedings of the National Academy of Sciences, 2009
- Conformational inhibition of the hepatitis C virus internal ribosome entry site RNANature Chemical Biology, 2009
- Pentamidine binds to tRNA through non-specific hydrophobic interactions and inhibits aminoacylation and translationNucleic Acids Research, 2008
- The worldwide Protein Data Bank (wwPDB): ensuring a single, uniform archive of PDB dataNucleic Acids Research, 2006
- NMRPipe: A multidimensional spectral processing system based on UNIX pipesJournal of Biomolecular NMR, 1995